Abstract:Abstract Introduction Obstructive sleep apnea (OSA) is an increasingly prevalent sleep-related breathing disorder linked to cognitive dysfunction and daytime sleepiness. Positive airway pressure (PAP) therapy, the first-line treatment for OSA, may improve cognitive function and sleepiness, but responses vary. Hypoglossal nerve stimulation (HGNS) is a novel and effective PAP alternative, but its effect on mitigating cognitive decline secondary to OSA is unknown. In the first sham-controlled HGNS trial, we evaluated the effect of HGNS therapy on cognitive measures and patient-reported outcomes (PROs) in patients with moderate-severe OSA. Methods In a double-blind, sham-controlled, randomized crossover therapy trial, patients already stabilized on HGNS therapy underwent four weeks of active and four weeks of sham HGNS, each with a 1-week washout period. Sham therapy was defined as the lowest voltage at which HGNS was sensed by the patient or visualized by the clinician. Cognitive measures (Psychomotor Vigilance Test [PVT], Digit Symbol Substitution Task [DSST]) and sleep-related PROs (Epworth Sleepiness Scale [ESS], Snoring Visual Analog Scale [VAS], Insomnia Severity Index [ISI], Functional Outcomes of Sleep Questionnaire [FOSQ]) were assessed after each 4-week period and compared between active and sham therapy. Results Sixty randomized patients were included. On average, participants were elderly (67.3±9.9 years), overweight (BMI 28.7±4.6 kg/m2) and had severe OSA prior to HGNS therapy (AHI 33.1±14.9 events/hour). Patients’ AHI decreased to 23.0±15.6 events/hour with sham therapy (p=0.0001) and 18.1±14.8 events/hour with active therapy (p< 0.0001), with a 4.9 event/hour decrease between active and sham therapy (p=0.014). There were no significant differences in performance measures on PVT or DSST between active and sham HGNS. All sleep-related PROs were statistically significant with moderately large (effect sizes ~0.41-0.56) improvements following active HGNS. Conclusion The HGNS system permits a unique investigation of the therapy “on/off” effect on measures of cognitive function. In the first sham-controlled, randomized crossover trial of patients using HGNS, all sleep-related PROs, but not objective measures of cognition, were significantly different between sham and active (therapeutic) levels. These findings warrant additional investigation examining the relationship between subjective and objective measures of function in OSA. Support (if any) American Heart Association (17SDG33670349) American Sleep Medicine Foundation (176-JF-17) National Institutes of Health (P01-HL094307)

1094 Who Gets the Stim?: A Demographic Analysis of Hypoglossal Nerve Stimulator Patients

1098 Hypoglossal Nerve Stimulation Program Analysis and Financial Impact over 6 Months

0594 Novel Device to Simulate Hypoglossal Nerve Stimulation Response to Predict Surgical Success

1160 Examining Criteria in Hypoglossal Nerve Stimulation: A Case Insight

Clinical Predictors of OSA Treatment Success Following Implantation of a Hypoglossal Nerve Stimulation Device

What are the Predictors of Success with Hypoglossal Nerve Stimulation?

0590 Hypoglossal Nerve Stimulation for OSA – a Systematic Review of Adverse Events in Clinical Trials & Real-world-data

0591 Improving Efficiency & Patient Outcomes Using Longitudinal Monitoring via a HSAT with Hypoglossal Nerve Stimulation

Treatment Outcomes in Awake Endoscopy With Advanced Programming in Hypoglossal Nerve Stimulation

Hypoglossal nerve stimulation versus positive airway pressure therapy for obstructive sleep apnea

0540 Comparing Periodic Limb Movements of Sleep Before and After Hypoglossal Nerve Stimulation Therapy

Are There Hidden Adverse Events in Hypoglossal Nerve Stimulation: Comparing Social Media and a Federal Database

The Impact of Hypoglossal Nerve Stimulation on Secondary Health Outcomes

0459 Cardiovascular Endpoints for Obstructive Sleep Apnea with Twelfth Nerve Stimulation: Measures of Sleep-Related Function

0589 Evaluating the Impact of Sleep Position on Efficacy of Hypoglossal Nerve Stimulation

Hypoglossal Nerve Stimulation Therapy Outcomes in Apnea- Versus Hypopnea-Predominant Patients

Implementing a Streamlined Hypoglossal Nerve Stimulator Pathway: Cost, Time to Surgery, and Outcomes

Upper Airway Stimulation for Children and Adolescents with Down Syndrome: Long‐Term Follow‐Up

How we measure hypoglossal nerve stimulator outcome matters: titration versus single amplitude efficacy sleep studies

Comparison of Home Sleep Devices and Sleep Study Testing in Hypoglossal Nerve Stimulation Patients

1228 The Impact of Modified Uvulopalatopharyngoplasty as a Bridge to Hypoglossal Nerve Stimulation Eligibility